Literature DB >> 25151849

Screening of human papillomavirus infection in women with systemic sclerosis.

M Martin1, C Mougin, J-L Prétet, H Gil, N Meaux-Ruault, E Puzenat, R Ramanah, F Aubin, A Touzé, P Coursaget, E Jacquin, N Magy-Bertrand.   

Abstract

OBJECTIVES: High risk human papilloma-viruses (HR HPV) are associated with risk of cervical dysplasia and carcinoma. The risk is increased in patients with immune deficiency or auto-immune disease as systemic lupus erythematosus. Currently, no data are available about the human papillomavirus status in women with systemic sclerosis (SSc).
METHODS: Thirty-one women with SSc were evaluated for cervical HPV infection and dysplasia, and compared to fifty age-matched control. Cervical swabs were tested by the INNO-LiPA assay®. Serum antibodies against HPV 16 and 18 were assessed using enzyme-linked immunosorbent assay in the SSc group.
RESULTS: The overall HPV frequency was comparable between SSc and controls (32% vs. 38%), as well as the HR HPV frequency (28% vs. 34%), but infection by ≥2 HPV was two times more frequent in the SSc group (50% vs. 26% of the HPV positive samples). The most prevalent genotype was 52 in the SSc group (12%), and 52/53 in the control group (8% for both). Pap smears were within the normal range. Seropositivity for HPV 16 and 18 was 13% and 6.5%, respectively. A diffuse systemic sclerosis and a younger age at first intercourse were more frequent in cases of overall HPV positivity. Current smoking and a higher number of sexual partners were only observed in cases of seropositivity.
CONCLUSIONS: This is the first study to evaluate HPV status in women with SSc. HR HPV52 was the most common genotype with a greater multi-HPV infection rate. This result needs to be confirmed in a larger study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25151849

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

Review 1.  Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.

Authors:  Giuseppe Murdaca; Giovanni Noberasco; Dario Olobardi; Claudio Lunardi; Matteo Maule; Lorenzo Delfino; Massimo Triggiani; Chiara Cardamone; Devis Benfaremo; Gianluca Moroncini; Angelo Vacca; Nicola Susca; Sebastiano Gangemi; Paola Quattrocchi; Laura Sticchi; Giancarlo Icardi; Andrea Orsi
Journal:  Vaccines (Basel)       Date:  2021-12-02

2.  Gynaecological Screening for Cervical and Vulvar Malignancies in a Cohort of Systemic Sclerosis Patients: Our Experience and Review of the Literature.

Authors:  M Colaci; D Giuggioli; G Cassone; C Vacchi; F Campomori; F Boselli; M Sebastiani; A Manfredi; C Ferri
Journal:  Int J Rheumatol       Date:  2015-10-18

Review 3.  Systemic Sclerosis and Malignancy: A Review of Current Data.

Authors:  Nabil Zeineddine; Lara El Khoury; Joseph Mosak
Journal:  J Clin Med Res       Date:  2016-07-30

Review 4.  Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.

Authors:  Alexandre Thibault Jacques Maria; Léo Partouche; Radjiv Goulabchand; Sophie Rivière; Pauline Rozier; Céline Bourgier; Alain Le Quellec; Jacques Morel; Danièle Noël; Philippe Guilpain
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

5.  Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

Authors:  Victoria Furer; Christien Rondaan; Marloes Heijstek; Sander van Assen; Marc Bijl; Nancy Agmon-Levin; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha Crnkic Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.